taxol/kraujavimas

Nuoroda įrašoma į mainų sritį

Pasirinkite rūšiavimo tipą

Puslapis 1 nuo 30 rezultatus

High-dose chemotherapy and autologous stem cell support followed by post-transplant doxorubicin and taxol as initial therapy for metastatic breast cancer: hematopoietic tolerance and efficacy.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A multistep HDC regimen was designed as first-line chemotherapy for MBC. Twenty-four patients with MBC and no previous chemotherapy for metastatic disease were treated with high-dose cyclophosphamide (5000 mg/m2), and etoposide (1000 mg/m2) (CyVP16), followed by granulocyte colony-stimulating factor

Taxol and embryonic development in the chick.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Taxol, an inhibitor of microtubule disassembly, is currently under investigation in the therapy of several human cancers. The current investigation was undertaken to characterize potential taxol developmental toxicity in chicks. On one of days 1-4 of incubation, taxol was administered in

Acute Local Spontaneous and Profuse Gingival Hemorrhage during Neoadjuvant Treatment with Paclitaxel and Trastuzumab.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

This case report describes a 33-year-old female currently undergoing breast cancer treatment following the AC-T-T (doxorubicin hydrochloride (Adriamycin) and cyclophosphamide followed by paclitaxel (Taxol) and trastuzumab (Herceptin)) treatment regimen. Her chief complaint at the time of the

Platelet spherocytosis: a new bleeding disorder.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The present study evaluated a child with thrombocytopenia and a rare congenital bleeding disorder associated with platelet spherocytosis. Differential interference phase contrast microscopy (DIC) revealed that his platelets were spherical in form. Examination of thin sections in the electron

The influence of the combined treatment with Vadimezan (ASA404) and taxol on the growth of U251 glioblastoma xenografts.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND One of the most important biological characteristics of Glioblastoma multiforme (GBM) is high vascular density. Vadimezan (ASA404, DMXAA) belongs to the class of small molecule vascular disrupting agents (VDA) that cause disruption of established tumor vessels and subsequent tumor

Phase I trial of intratumoral liposome E1A gene therapy in patients with recurrent breast and head and neck cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE We conducted a Phase 1 study to determine the maximal tolerated dose and maximum biologically active dose of the E1A gene delivered by intratumoral injection as a lipid complex with 3 beta[N-(n',n'-dimethylaminoethane)-carbamoyl] cholesterol/dioleoylphosphatidyl-ethanolamine (tgDCC-E1A).

[Primary clear cell carcinoma of the cervix: report of five cases and review of the literature].

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE To explore the clinical diagnostic and therapeutic characteristics, prognostic factors of patients with primary clear cell carcinoma of the cervix. METHODS The clinical, pathologic and follow-up data of patients with primary clear cell carcinoma of the cervix treated in our hospital from

Clinical relevance of genetic polymorphisms in the human CYP2C subfamily.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

The human CYP2Cs are an important subfamily of P450 enzymes that metabolize approximately 20% of clinically used drugs. There are four members of the subfamily, CYP2C8, CYP2C9, CYP2C19, and CYP2C18. Of these CYP2C8, CYP2C9, and CYP2C19 are of clinical importance. The CYP2Cs also metabolize some

Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

A dose-finding study was set up to identify the optimal dose of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin for phase II studies in patients with advanced chemotherapy-naive non-small cell lung cancer (NSCLC). The influence of drug sequence on

Radiosurgery of isolated cerebral vessels following administration of paclitaxel in the rat.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

OBJECTIVE Progressive obliteration occurs in arteriovenous malformations (AVMs) after radiosurgery; however, the risk of hemorrhage remains until the obliteration process is complete. The authors sought to enhance the radiation effect and reduce the risk of hemorrhage by facilitating faster vessel

Paclitaxel and carboplatin in the treatment of advanced non-small cell lung cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Based on the superior response rates (21% to 24%) of patients treated with single-agent paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in Eastern Cooperative Oncology Group and M.D. Anderson Cancer Center trials in non-small cell lung cancer (NSCLC) and on the superior 1-year

Preliminary results of a phase II study of paclitaxel and cisplatin in patients with non-small cell lung cancer.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin are cytotoxic drugs active against non-small cell lung cancer (NSCLC) that possess additive cytotoxicity in animal tumors. Paclitaxel and cisplatin are active in patients with advanced NSCLC when given on a 3-weekly

A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial. METHODS Patients were sequentially assigned to one of two treatment arms. In addition

Carboplatin-related hematuria and acute renal failure.

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

Cisplatin is a potent tubular toxin with a high incidence of nephrotoxicity. Carboplatin is considered less nephrotoxic but can still cause tubular injury and interstitial nephritis in patients who have been previously treated with cisplatin. The affected individuals usually have nonoliguric renal

Radical Surgery in Advanced Cervical Cancer Patients Receiving Bevacizumab-Containing Chemotherapy: A "Real Life Experience".

Straipsnius versti gali tik registruoti vartotojai

Prisijungti Registracija

BACKGROUND Platinum-based chemotherapy plus bevacizumab is the new standard of care in stage IVB cervical cancer (CC) patients. In this new scenario, radical surgery could be offered in selected cases with an optimal clinical response. Potential surgical complications related to previous bevacizumab

Ankstesnis
1
2
Kitas

Prisijunkite prie mūsų
„Facebook“ puslapio

Herbal & Natural Medicine

Išsamiausia vaistinių žolelių duomenų bazė, paremta mokslu

Dirba 55 kalbomis
Žolelių gydymas, paremtas mokslu
Vaistažolių atpažinimas pagal vaizdą
Interaktyvus GPS žemėlapis - pažymėkite vaistažoles vietoje (netrukus)
Skaitykite mokslines publikacijas, susijusias su jūsų paieška
Ieškokite vaistinių žolelių pagal jų poveikį
Susitvarkykite savo interesus ir sekite naujienas, klinikinius tyrimus ir patentus

Įveskite simptomą ar ligą ir perskaitykite apie žoleles, kurios gali padėti, įveskite žolę ir pamatykite ligas bei simptomus, nuo kurių ji naudojama.
* Visa informacija pagrįsta paskelbtais moksliniais tyrimais